Celcuity+Logo.jpg
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
22 août 2023 16h01 HE | Celcuity Inc.
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 ...
Celcuity+Logo.jpg
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
10 août 2023 16h04 HE | Celcuity Inc.
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer...
Celcuity+Logo.jpg
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
03 août 2023 07h30 HE | Celcuity Inc.
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it...
Celcuity+Logo.jpg
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
31 juil. 2023 08h00 HE | Celcuity Inc.
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that...